Products Categories
| CAS No.: | 55268-75-2 |
|---|---|
| Name: | Cefuroxime |
| Molecular Structure: | |
|
|
|
| Formula: | C16H16N4O8S |
| Molecular Weight: | 424.391 |
| Synonyms: | Cefaloxime;Cefasyn;Cefuroxim;Cefuroxime acid;Ketocef;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,3-[[(aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-furanyl(methoxyimino)acetyl]amino]-8-oxo-,(6R,7R)- (9CI);5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,3-[[(aminocarbonyl)oxy]methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-,[6R-[6a,7b(Z)]]-;Biofuroksym;Biofuroxim; |
| EINECS: | 259-560-1 |
| Density: | 1.76 g/cm3 |
| Melting Point: | 171.5-173 °C |
| Solubility: | 145mg/L at 25℃ |
| Appearance: | White to ivory white crystalline powder |
| Hazard Symbols: |
 Xn
|
| Risk Codes: | 42/43 |
| Safety: | 22-24-37-45 |
| PSA: | 199.06000 |
| LogP: | 0.49310 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 717878-06-31-(4-fluorophenyl)-4-nitro-1H-imidazole
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
- 123-72-8Butyraldehyde
- 56830-58-12,5-Diamino-4,6-dihydroxypyrimidine hydrochloride
- 144143-96-4Eprosartan mesylate
- 14999-43-0Glucosamine sulfate
- 5419-55-6Boricacid (H3BO3), tris(1-methylethyl) ester
- 63148-57-2Poly(methylhydrosiloxane)
- 507-09-5Thioacetic acid
- 7220-79-3Methylene Blue trihydrate
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Specification
The Cefuroxim is an organic compound with the formula C16H16N4O8S. The IUPAC name of this chemical is (6R, 7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl] amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. With the CAS registry number 55268-75-2, the product's categories are Antibiotics; Bacteriostatic Antibiotics; beta-Lactam StructureAlphabetic; C; CA - CG; Chemical Structure; Principle.
The Cefuroxim is the second-generation cephalosporin antibiotics against Gram-positive bacteria and-negative bacteria have a strong antibacterial or bactericidal effect on the β-lactamase stability, and injection administration. It is used to susceptible ones caused by urinary tract infections, respiratory infections, soft tissue infections, obstetrics and gynecology diseases, infections, gonorrhea, meningitis.
Physical properties about Cefuroxim are: (1)ACD/LogP: 0.84; (2)# of Rule of 5 Violations: 1; (3)ACD/LogD (pH 5.5): -2.07; (4)ACD/LogD (pH 7.4): -2.91; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 1; (7)ACD/KOC (pH 5.5): 1; (8)ACD/KOC (pH 7.4): 1; (9)#H bond acceptors: 12; (10)#H bond donors: 4; (11)#Freely Rotating Bonds: 8; (12)Polar Surface Area: 156.49 Å2; (13)Index of Refraction: 1.734; (14)Molar Refractivity: 96.66 cm3; (15)Molar Volume: 241 cm3; (16)Polarizability: 38.32×10-24cm3; (17)Surface Tension: 78 dyne/cm; (18)Density: 1.76 g/cm3.
Uses of Cefuroxim: it can be used to produce 3-carbamoyloxymethyl-7-(2-furan-2-yl-2-methoxyimino-acetylamino)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 4-methoxy-benzyl ester at ambient temperature. It will need reagent NaHCO3 and solvent dimethylformamide, dioxane . The yield is about 75%.
.png)
.gif)
When you are using this chemical, please be cautious about it as the following:
It may cause sensitisation by inhalation and skin contact. Besides, this chemical is irritating to eyes, respiratory system and skin. When you are using it, wear suitable gloves, do not breathe dustand avoid contact with skin. In case of accident or if you feel unwell seek medical advice immediately (show the label where possible).
You can still convert the following datas into molecular structure:
(1)SMILES: O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=NOC)c3occc3)COC(=O)N)C(=O)O
(2)InChI: InChI=1/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/t10-,14-/m1/s1
(3)InChIKey: JFPVXVDWJQMJEE-QMTHXVAHBS
(4)Std. InChI: InChI=1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/t10-,14-/m1/s1
(5)Std. InChIKey: JFPVXVDWJQMJEE-QMTHXVAHSA-N
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| man | TDLo | intravenous | 64mg/kg/16H-I (64mg/kg) | BEHAVIORAL: TOXIC PSYCHOSIS | Lancet. Vol. 1, Pg. 965, 1984. |
| mouse | LD50 | intramuscular | > 2gm/kg (2000mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: ATAXIA | Chemotherapy Vol. 27(Suppl, |
| mouse | LD50 | intraperitoneal | > 10gm/kg (10000mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Chemotherapy Vol. 27(Suppl, |
| mouse | LD50 | intravenous | 10400mg/kg (10400mg/kg) | Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. Vol. 17, Pg. 233, 1979. | |
| mouse | LD50 | oral | > 10gm/kg (10000mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: ATAXIA | Chemotherapy Vol. 27(Suppl, |
| mouse | LD50 | subcutaneous | > 10gm/kg (10000mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: ATAXIA | Chemotherapy Vol. 27(Suppl, |
| rabbit | LD50 | intramuscular | > 300mg/kg (300mg/kg) | Chemotherapy Vol. 27(Suppl, | |
| rabbit | LD50 | intravenous | > 1500mg/kg (1500mg/kg) | BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Chemotherapy Vol. 27(Suppl, |
| rat | LD50 | intramuscular | > 2gm/kg (2000mg/kg) | Chemotherapy Vol. 27(Suppl, | |
| rat | LD50 | intraperitoneal | > 10gm/kg (10000mg/kg) | Chemotherapy Vol. 27(Suppl, | |
| rat | LD50 | intravenous | > 8gm/kg (8000mg/kg) | Chemotherapy Vol. 27(Suppl, | |
| rat | LD50 | oral | 10gm/kg (10000mg/kg) | Chemotherapy Vol. 27(Suppl, | |
| rat | LD50 | subcutaneous | > 10gm/kg (10000mg/kg) | Chemotherapy Vol. 27(Suppl, |